Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
Wiesner
R H
RH
Division of Hepatology, Mayo Clinic, Rochester, Minnesota 55905.
Porayko
M K
MK
Wahlstrom
H E
HE
Gores
G J
GJ
Kamath
P S
PS
Hay
J E
JE
Krom
R A
RA
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D001706:Biopsy; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D015994:Incidence; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D012189:Retrospective Studies; D016559:Tacrolimus / Q000097:blood / Q000627:therapeutic use; D013997:Time Factors
D016572:Cyclosporine; D001379:Azathioprine; D001663:Bilirubin; D011241:Prednisone; D016559:Tacrolimus